Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes

Current Treatment Options in Cardiovascular Medicine
Daniel R MangelsTaisei Kobayashi

Abstract

Antiplatelet therapies are pivotal treatments in the management of acute coronary syndrome (ACS) with or without revascularization. In recent years, the use of P2Y12 antagonists prior to catheterization, so-called pretreatment, has been questioned, particularly in patients who may be at higher bleeding risks. The purpose of this review was to evaluate the current literature on contemporary and novel antiplatelet therapy in the pretreatment and treatment of ACS. The P2Y12 receptor antagonists are associated with substantial reductions in morbidity and mortality for all types of ACS but only clopidogrel and ticagrelor have sufficient evidence for use in the pretreatment setting. The data regarding prasugrel support the use in patients undergoing percutaneous intervention (PCI). The glycoprotein IIa/IIIb antagonists are the most optimal for use in high-risk ACS as an adjuvant therapy during and after PCI. In summary, although all P2Y12 antagonists have morbidity- and mortality-reducing effects in ACS, only clopidogrel and ticagrelor have sufficient evidence in the pretreatment setting. Newer antiplatelet therapies, most notably the protease-activated receptor 1 antagonists, are evolving and promising but are associated with greate...Continue Reading

References

May 23, 1998·The New England Journal of Medicine·UNKNOWN Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS)
Jun 23, 2001·The New England Journal of Medicine·C P CannonUNKNOWN TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis
Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Aug 25, 2001·Lancet·S R MehtaUNKNOWN Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Nov 19, 2002·JAMA : the Journal of the American Medical Association·Steven R SteinhublUNKNOWN CREDO Investigators. Clopidogrel for the Reduction of Events During Observation
Mar 27, 2003·Journal of Cardiovascular Pharmacology·Martin MoserJohannes Ruef
Aug 9, 2003·Expert Opinion on Drug Safety·Garry M Walsh
Feb 15, 2007·JAMA : the Journal of the American Medical Association·Gregg W StoneUNKNOWN ACUITY Investigators
Mar 6, 2007·Thrombosis and Haemostasis·Jolanta Siller-MatulaKurt Huber
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Dec 25, 2008·The New England Journal of Medicine·Jessica L MegaMarc S Sabatine
Apr 1, 2009·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN EARLY ACS Investigators
Jul 17, 2009·Cardiovascular Therapeutics·Steen Husted, J J J van Giezen
Oct 10, 2009·Expert Review of Cardiovascular Therapy·José Luis FerreiroDominick J Angiolillo
Nov 17, 2009·The New England Journal of Medicine·Robert A HarringtonDeepak L Bhatt
Jan 19, 2010·Lancet·Christopher P CannonUNKNOWN PLATelet inhibition and patient Outcomes Investigators
Sep 8, 2010·The New England Journal of Medicine·Shamir R MehtaSalim Yusuf
Apr 12, 2011·Thrombosis and Haemostasis·Robert F Storey
Jan 19, 2012·JAMA : the Journal of the American Medical Association·Dominick J AngiolilloUNKNOWN BRIDGE Investigators
Apr 25, 2012·European Journal of Clinical Pharmacology·Paul StatkevichDavid L Cutler
Aug 28, 2012·The New England Journal of Medicine·Matthew T RoeUNKNOWN TRILOGY ACS Investigators
Dec 19, 2012·Circulation·Patrick T O'GaraUNKNOWN American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Mar 12, 2013·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PHOENIX Investigators
May 24, 2013·Clinical Pharmacology and Therapeutics·S A ScottUNKNOWN Clinical Pharmacogenetics Implementation Consortium
Sep 3, 2013·The New England Journal of Medicine·Gilles MontalescotUNKNOWN ACCOAST Investigators
Oct 22, 2013·Expert Review of Cardiovascular Therapy·Francesco FranchiDominick J Angiolillo
Feb 8, 2014·Current Atherosclerosis Reports·Carlos G Santos-GallegoJuan José Badimón
Sep 2, 2014·The New England Journal of Medicine·Gilles MontalescotUNKNOWN ATLANTIC Investigators

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.